Marshall Wace, LLP Cardiol Therapeutics Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 13,193 shares of CRDL stock, worth $15,963. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,193Holding current value
$15,963% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRDL
# of Institutions
45Shares Held
7.09MCall Options Held
4.9KPut Options Held
3.8K-
Tejara Capital LTD London, X03.12MShares$3.77 Million2.61% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD882KShares$1.07 Million0.23% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9796KShares$962,7060.31% of portfolio
-
Cambridge Investment Research Advisors, Inc.331KShares$399,9110.0% of portfolio
-
Envestnet Asset Management Inc310KShares$374,7170.0% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $75M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...